Buspirone improves symptoms in functional dyspepsia

Buspirone improves symptoms in functional dyspepsia
Buspirone, a 5-hydroxytryptamine 1A receptor agonist, improves symptom severity in patients with functional dyspepsia, according to a proof-of-concept study published in the November issue of Clinical Gastroenterology and Hepatology.

(HealthDay)—Buspirone, a 5-hydroxytryptamine 1A receptor agonist, improves symptom severity in patients with functional dyspepsia (FD), according to a proof-of-concept study published in the November issue of Clinical Gastroenterology and Hepatology.

Jan Tack, M.D., Ph.D., from the University of Leuven in Belgium, and colleagues conducted a crossover study involving 17 patients (13 women; mean age, 38.5 years) to examine the effects of buspirone on the symptoms and mechanisms of FD. In the first of two treatment periods, seven participants were randomized to receive buspirone (10 mg, three times daily for four weeks) and 10 were given 15 minutes before meals. Following a two-week washout period, patients switched groups for the second period.

The researchers found that buspirone correlated with a significant reduction in the overall severity of symptoms of dyspepsia and individual symptoms of postprandial fullness, early satiation, and upper abdominal bloating, compared to the placebo, which had no significant effect. Buspirone significantly increased gastric accommodation, compared with placebo, and delayed gastric emptying of liquids, but did not alter the rate of gastric emptying of solids or sensitivity to gastric distention. Adverse events were similar when patients received buspirone or placebo.

"In patients with FD, four weeks of administration of buspirone significantly improved symptoms and gastric accommodation, compared with placebo, whereas gastric emptying of liquids was delayed," the authors write.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

In diabetes, gastric emptying remains stable over time

Aug 24, 2012

(HealthDay)—Gastric emptying of solids and liquids and gastrointestinal symptoms remain stable over time in patients with long-term type 1 and type 2 diabetes, according to a study published online Aug. ...

A potential treatment for gastric motility disorders

Jun 10, 2009

GES or pacing has been under investigation as a potential therapy for gastrointestinal motility disorders. Conventionally, GES is performed using a single pair of electrodes or single-channel GES. However, few studies have ...

Recommended for you

Saudi Arabia reports pilgrim infected with MERS

2 hours ago

In the past 24 hours, Saudi Arabia has reported four new deaths from a Middle East virus related to SARS and 36 more cases of infection, including a Turkish pilgrim in Mecca.

User comments